FLUTEMETAMOL F-18: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ge Healthcare	VIZAMYL	flutemetamol f-18	INJECTABLE;INTRAVENOUS	203137	NDA	GE Healthcare Inc. (Medi-Physics, Inc. dba GE Healthcare)	17156-067-30	1 VIAL, MULTI-DOSE in 1 CONTAINER (17156-067-30) / 30 mL in 1 VIAL, MULTI-DOSE	2014-01-01
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Flutemetamol F-18 is a radiopharmaceutical used in positron emission tomography (PET) imaging for the detection of amyloid plaques in the brain, a hallmark of Alzheimer's disease. The reliable and efficient supply of this radiotracer is critical for diagnostic accuracy and patient care. Production involves the synthesis of flutemetamol and its subsequent labeling with Fluorine-18 (F-18), a short-lived radioisotope requiring on-site or near-site cycloton production and rapid delivery.

Who are the Key Suppliers for Flutemetamol F-18 Production?

The supply chain for flutemetamol F-18 can be segmented into several key areas: the synthesis of the flutemetamol precursor, the production of F-18, and the radiolabeling process. While a single, fully integrated supplier is rare, several companies and institutions contribute essential components and services.

Precursor Synthesis

The synthesis of the flutemetamol precursor molecule is a multi-step chemical process. Companies specializing in fine chemical synthesis and active pharmaceutical ingredient (API) manufacturing are involved.

GE Healthcare (now Curium): Historically a major player in PET radiotracers, GE Healthcare developed and commercialized flutemetamol F-18 under the brand name GEH-2368. While they are a primary source for the final radiolabeled product, their internal capabilities likely extend to precursor synthesis or close partnerships with contract manufacturing organizations (CMOs).
Contract Manufacturing Organizations (CMOs): Several global CMOs with expertise in complex organic synthesis and GMP (Good Manufacturing Practice) compliant production can produce the flutemetamol precursor. Identifying specific CMOs for this niche precursor requires direct engagement, as it is often not publicly disclosed for proprietary reasons. However, companies with a strong track record in radiopharmaceutical precursor manufacturing are potential candidates. These include:
- Biotage AB: While known for purification and synthesis tools, Biotage also has custom synthesis capabilities that could be leveraged for complex organic molecules.
- WuXi AppTec: A large global CRO/CMO that offers comprehensive chemical synthesis services, including GMP manufacturing for APIs and intermediates.
- Lonza: A global supplier to the pharmaceutical and biotechnology industries, Lonza provides custom development and manufacturing services for small molecules.

Fluorine-18 Production

Fluorine-18 has a half-life of approximately 109.8 minutes. This necessitates that F-18 be produced either at the site where radiolabeling occurs or transported very rapidly from a nearby production facility. F-18 is typically produced via the ¹⁸O(p,n)¹⁸F nuclear reaction using a medical cyclotron.

Cyclotron Manufacturers: Companies that design, build, and service medical cyclotrons are integral to the F-18 supply chain, enabling institutions to produce their own F-18.
- Trillium Therapeutics (now part of HealthCare Royalty Partners): Originally developed cyclotrons for radiopharmaceutical production.
- IBA (Ion Beam Applications): A leading manufacturer of medical cyclotrons and radiopharmaceutical production systems. IBA cyclotrons are widely used in hospitals and research centers for F-18 production.
- GE Healthcare (now Curium): Also offers cyclotron systems and associated equipment for F-18 production.
- PETNET Solutions (a division of Siemens Healthineers): Operates a network of radiopharmacies that produce and distribute F-18 labeled radiotracers, including flutemetamol F-18, to healthcare facilities. They manage their own cyclotron infrastructure and F-18 production.

Radiolabeling and Distribution

The final step is the radiolabeling of the flutemetamol precursor with F-18, followed by purification, quality control, and distribution to imaging centers. This is typically performed by specialized radiopharmacies or imaging facilities with in-house radiochemistry capabilities.

Curium (formerly GE Healthcare's Pharmaceutical Diagnostics business): As the developer of flutemetamol F-18 (NeuraCeq), Curium is a primary supplier of the finished radiotracer in many regions. They operate a global network of radiopharmacies and production facilities.
PETNET Solutions (Siemens Healthineers): Operates a substantial network of radiopharmacies across the United States and internationally, supplying various PET tracers, including flutemetamol F-18, to hospitals and clinics. Their distribution model relies on proximity to cyclotron facilities and efficient logistics for short-lived isotopes.
Academic Medical Centers and Research Institutions: Many leading hospitals and research universities with PET imaging programs and in-house cyclotrons are equipped to synthesize and radiolabel flutemetamol F-18 for their own clinical and research needs. Examples include:
- Massachusetts General Hospital
- Mayo Clinic
- University of Pittsburgh Medical Center
- University College London (UCL)

What are the Regulatory and Quality Control Requirements for Flutemetamol F-18 Supply?

The production and distribution of radiopharmaceuticals like flutemetamol F-18 are subject to stringent regulatory oversight and quality control measures to ensure patient safety and diagnostic efficacy.

Regulatory Bodies and Approvals

Food and Drug Administration (FDA) in the U.S.: The FDA regulates radiopharmaceuticals under the same framework as other drugs. Approval is required for marketing, including New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs) for generics.
- Current Status: Flutemetamol F-18 (as NeuraCeq) received FDA approval in May 2018 for diagnostic imaging of beta-amyloid neuritic plaque density in adult patients with mild, moderate, or severe impairment suspected of having Alzheimer’s disease or other causes of dementia.
European Medicines Agency (EMA) in Europe: The EMA is responsible for the scientific evaluation, supervision, and safety monitoring of medicines in the European Union.
- Current Status: Flutemetamol F-18 (as Neuraceq) received marketing authorization from the EMA in March 2019.
Other National Regulatory Agencies: Similar agencies in other countries (e.g., Health Canada, Pharmaceuticals and Medical Devices Agency (PMDA) in Japan) also regulate radiopharmaceuticals.

Good Manufacturing Practice (GMP)

All manufacturing processes, from precursor synthesis to final product formulation, must adhere to GMP guidelines.

Key GMP Principles:
- Process Validation: Ensuring that manufacturing processes consistently produce a product meeting predetermined specifications and quality attributes.
- Equipment Qualification: Verifying that all manufacturing equipment is suitable for its intended use and operates correctly.
- Personnel Training: Ensuring that all personnel involved in manufacturing are adequately trained and qualified.
- Quality Control Testing: Comprehensive testing of raw materials, in-process samples, and finished products for identity, purity, strength, and quality. This includes assays for radiochemical purity and specific activity.
- Documentation: Maintaining detailed records of all manufacturing and quality control activities.

Radiochemical Purity and Specific Activity

Radiochemical Purity: The percentage of radioactivity in a sample that is in the desired chemical form (flutemetamol F-18). Regulatory limits are typically very high, often >95%.
Specific Activity: The amount of radioactivity per unit mass or moles of the unlabeled compound. Higher specific activity is desirable for PET tracers to minimize the injected mass of the non-radioactive tracer, reducing potential off-target pharmacology. For F-18 tracers, specific activity is influenced by the F-18 production method and labeling efficiency.

Shelf-Life and Stability

Due to the short half-life of F-18, the shelf-life of flutemetamol F-18 is very short, typically within hours of calibration. Stability studies are crucial to ensure the radiochemical purity remains within acceptable limits throughout this short period.

What are the Challenges and Opportunities in the Flutemetamol F-18 Supply Chain?

The unique nature of radiopharmaceuticals, particularly those with short-lived isotopes like F-18, presents distinct challenges and opens up specific opportunities for suppliers and users.

Challenges

Logistical Complexity for Short Half-Life Isotope: The 109.8-minute half-life of F-18 is the primary logistical hurdle.
- Production Proximity: Requires cyclotrons to be located at or very near the radiolabeling facility, or robust, rapid transport networks from centralized production sites. This limits the geographic reach of single production facilities.
- Just-in-Time Manufacturing: Production schedules must be tightly coordinated with patient appointments to minimize waste.
- Cold Start: "Cold start" refers to the time required to bring a cyclotron online and produce a sufficient target of F-18, adding to the overall preparation time.
High Capital Investment:
- Cyclotrons: Medical cyclotrons represent a significant capital expenditure, ranging from $1 million to $3 million or more, plus ongoing operational and maintenance costs.
- Radiopharmacy Infrastructure: Setting up and maintaining GMP-compliant radiopharmacies with shielded hot cells, automated synthesis modules, and quality control equipment is costly.
Regulatory Burden: Navigating the complex regulatory landscape for radiopharmaceuticals in different countries requires significant expertise and resources.
Limited Number of Specialized Suppliers: The niche nature of radiopharmaceutical synthesis and production means fewer companies possess the specialized expertise and infrastructure compared to traditional pharmaceuticals.
Technical Expertise: Operating cyclotrons, performing radiolabeling, and conducting quality control require highly specialized technical personnel, who are in limited supply.
Waste Management: Radioactive waste disposal adds a layer of complexity and cost to operations.

Opportunities

Growing Demand for Alzheimer's Diagnostics: The increasing global prevalence of Alzheimer's disease and the growing emphasis on early diagnosis drive demand for amyloid PET imaging agents like flutemetamol F-18.
Advancements in Cyclotron Technology: Newer, more compact, and cost-effective cyclotron designs are emerging, potentially lowering the barrier to entry for institutions.
Automation in Radiolabeling: Automated synthesis modules enhance efficiency, reproducibility, and safety in the radiolabeling process, reducing reliance on manual handling and improving yields.
Development of Novel F-18 Precursors: Research into more stable or easily synthesized precursors could streamline production.
Hub-and-Spoke Distribution Models: Centralized production hubs serving multiple satellite imaging centers can optimize resource utilization and supply chain efficiency for regions where individual cyclotron installation is not feasible.
Partnerships and Collaborations: Opportunities exist for partnerships between cyclotron manufacturers, precursor suppliers, radiopharmacies, and imaging centers to create integrated supply solutions.
Geographic Expansion: As regulatory pathways are cleared in new territories, opportunities arise for suppliers to expand their reach.

Conclusion

The supply chain for flutemetamol F-18 is characterized by its specialized nature, stringent regulatory requirements, and logistical challenges due to the short half-life of Fluorine-18. Key players include developers and distributors like Curium and Siemens Healthineers (PETNET Solutions), along with cyclotron manufacturers such as IBA and GE Healthcare. Academic medical centers and dedicated CMOs also play vital roles in precursor synthesis and localized F-18 production. Navigating this complex ecosystem requires a deep understanding of radiochemistry, GMP compliance, and efficient logistics to ensure timely and reliable delivery of this critical diagnostic agent. The growing demand for Alzheimer's diagnostics presents significant opportunities for growth and innovation within this specialized sector of the pharmaceutical industry.

Key Takeaways

Flutemetamol F-18 production relies on a specialized supply chain involving precursor synthesis, F-18 production via cyclotrons, and radiolabeling.
Curium and PETNET Solutions (Siemens Healthineers) are primary suppliers of the finished radiotracer, supported by cyclotron manufacturers like IBA and GE Healthcare.
Strict regulatory oversight (FDA, EMA) and adherence to GMP are critical for radiopharmaceutical quality and patient safety.
The 109.8-minute half-life of F-18 imposes significant logistical challenges, requiring proximity of production to use or rapid transport.
High capital investment in cyclotrons and radiopharmacies, coupled with technical expertise, are barriers to entry.
Growing demand for Alzheimer's diagnostics presents substantial market opportunities for suppliers.

Frequently Asked Questions

What is the primary role of a cyclotron in the flutemetamol F-18 supply chain? A cyclotron is used to produce the radioactive isotope Fluorine-18 (F-18) via nuclear reactions, such as the ¹⁸O(p,n)¹⁸F reaction, which is essential for labeling the flutemetamol precursor into the final PET imaging agent.
How does the short half-life of F-18 impact distribution strategies? The approximately 109.8-minute half-life of F-18 necessitates that radiolabeling and distribution occur very close to the point of patient administration. This leads to strategies involving on-site cyclotron production at imaging centers or a network of radiopharmacies strategically located near cyclotron facilities with rapid delivery logistics.
Can any pharmaceutical manufacturer produce flutemetamol F-18? No, production requires specialized expertise and infrastructure. This includes capabilities in complex organic synthesis for the precursor, access to medical cyclotrons for F-18 production, and GMP-compliant radiochemistry facilities for labeling, purification, and quality control.
What are the key quality control parameters for flutemetamol F-18? Key quality control parameters include identity, radiochemical purity (ensuring the radioactivity is primarily in the flutemetamol F-18 form), specific activity (radioactivity per unit mass), sterility, and absence of pyrogens. These ensure the safety and efficacy of the diagnostic agent.
What are the main cost drivers in the flutemetamol F-18 supply chain? Major cost drivers include the significant capital expenditure for medical cyclotrons and radiopharmacy infrastructure, the cost of target materials (e.g., enriched water for F-18 production), specialized personnel, regulatory compliance, and waste disposal for radioactive materials.

Citations

[1] U.S. Food and Drug Administration. (2018, May 25). FDA approves first drug to image amyloid neuritic plaque in Alzheimer’s disease. [Press Release]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-image-amyloid-neuritic-plaque-alzheimers-disease

[2] European Medicines Agency. (2019, March 29). Neuraceq. [European Public Assessment Report]. https://www.ema.europa.eu/en/medicines/human/EPAR/neuraceq

[3] IBA Worldwide. (n.d.). Medical Cyclotrons. Retrieved from https://www.iba-worldwide.com/products-and-services/medical-cyclotrons

[4] Siemens Healthineers. (n.d.). PETNET Solutions. Retrieved from https://www.siemens-healthineers.com/molecular-imaging/radiopharmacies/petnet-solutions

[5] Curium. (n.d.). Radiopharmaceuticals. Retrieved from https://www.curium.com/radiopharmaceuticals/

Suppliers and packagers for generic pharmaceutical drug: FLUTEMETAMOL F-18